→ A syndicate led by Arix Bioscience backed a big, $45 million round for LogicBio, an upstart gene therapy biotech focused on rare pediatric diseases. OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI, along with previous investor OrbiMed Israel Partners, took part in the round. The Cambridge, MA-based company uses tech developed by Adi Barzel at Tel Aviv University, Leszek Lisowski at Children’s Medical Research Institute, Australia, and Mark Kay at Stanford.
→ Biogen has a new communications chief. CEO Michel Vounatsos announced today that longtime industry pro and Novartis vet Catherine Steele will take charge of the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts. Vounatsos has been gathering together a new team to take the company forward after he took the helm at the beginning of this year.
→ Cambridge, MA-based Scholar Rock has chosen SRK-015, an inhibitor of the supracellular activation of myostatin, to develop for rare cases of spinal muscular atrophy, or SMA.
→ Cellectis $CLLS says it treated the first patient in its early-stage study for UCART123 in acute myeloid leukemia. The biotech says that this is the first use of an off-the-shelf CAR-T targeting CD123 in humans.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription